1472.6000 35.00 (2.43%)
NSE Dec 15, 2025 15:31 PM
Volume: 51,282
 

1472.60
2.43%
ICICI Securities Limited
Tatva Chintan’s Q4FY23 revenue rose 26.4% YoY to Rs1.2bn as SDA revenue recovered to Rs0.5bn, up 41% YoY. However, gross profit margin dip of 400bps to 39.8% was disappointing (partly from a change in product mix) considering the company has guided for a sequential improvement in margins.
Tatva Chintan Pharma has gained 44.74% in the last 3 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended